

ADVENTRX PHARMACEUTICALS INC

Form 8-K

May 22, 2006

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15 (d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) **May 22, 2006**

**ADVENTRX Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation)

**1-15803**

(Commission File Number)

**84-1318182**

(IRS Employer  
Identification No.)

**6725 Mesa Ridge Road, Suite 100**

**San Diego, California 92121**

(Address of principal executive offices) (Zip Code)

**(858) 552-0866**

(Company's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 2.02. Results of Operations and Financial Condition

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits.

**SIGNATURES**

**EXHIBIT INDEX**

EXHIBIT 99.1

EXHIBIT 99.2

---

**Table of Contents**

**Item 2.02. Results of Operations and Financial Condition**

On May 22, 2006, the Company filed Amendment No. 1 to its Form 10-Q for the three months ended March 31, 2006 previously filed on May 10, 2006, to incorporate by reference certain revised risk factor and revised business description disclosures set forth in the Company's Preliminary Prospectus Supplement dated May 16, 2006 (Subject to Completion) to Prospectus dated May 8, 2006 filed with the Commission under Rule 424(b)(5) (Registration No. 333-133729) on May 16, 2006. All risk factors and descriptions of the Company's business found in prior filings are superseded by these revised disclosures.

**Item 8.01. Other Events**

On May 22, 2006 the Company announced that it had withdrawn its proposed public offering of 15,495,867 shares of its common stock that it had previously announced on May 16, 2006.

On May 22, 2006, the Company announced that it had received FDA clearance under a Special Protocol Assessment to initiate its CoFactor Phase III Clinical Trial. In addition, the Company announced that it remains on track to initiate the Phase III clinical trial in Q2 2006.

The press releases issued by the Company on May 22, 2006 with respect to these matters are included with this report as exhibits.

**Item 9.01. Financial Statements and Exhibits.**

(d) The exhibit list required by this item is incorporated by reference to the Exhibit Index filed as part of this report.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ADVENTRX Pharmaceuticals, Inc.**

By: /s/ Evan M. Levine

Name: Evan M. Levine

Title: President & Chief Executive Officer

May 22, 2006

---

**Table of Contents**

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release of the Company dated May 22, 2006 re withdrawal of common stock offering.
99.2	Press Release of the Company dated May 22, 2006 re FDA Special Protocol Assessment